ABMD News and Press, ABIOMED Inc. From 12/29/20

As the year closes out, Abiomed (ABMD) is leading the S&P 500 constituents to become the highest gainer for 2020. With the 2.6% added today, the total return for the year is reaching 83.4% YTD, well outperforming the 17.8% gain in the SPDR S&P 500 Trust ETF (SPY). ...

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference (virtual) on Tuesday, January 12, ...

A 20-year back-testing study of my annual index for US-listed quality stocks reveals remarkably consistent outperformance on a risk-adjusted basis: Up to 21.1% in average annualized returns, 4.8% annualized alpha, average max drawdown of 8.8%, average Sortino ratio of 3.89, and an ave...

Abiomed (NASDAQ: ABMD) announces the first two patients in the world have been treated with the Abiomed Breethe OXY-1 System , a compact cardiopulmonary bypass system. The advanced ECMO technology pumps, oxygenates, and removes carbon dioxide from blood for patients whose lungs ...

Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has completed the first stage in its U.S. Food and Drug Administration (FDA) early feasibility study (EFS) and the FD...

The IShares Robotics and Artificial Intelligence Multisector ETF (IRBO) has delivered a strong performance during the last year. However, given the incredible gains made by tech stocks during this time and other risks, there may be mixed fortunes going ahead. In this case, diversi...

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference on Th...

Even though the biotech sector's coronavirus vaccine efforts have dominated the 2020 news cycle, those stocks don't always beat the market. When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better retur...

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday,...

Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy. ...